In a report released today, Benjamin Jackson CFA from Jefferies maintained a Buy rating on Galderma Group AG, with a price target of CHF160.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Benjamin Jackson CFA has given his Buy rating due to a combination of factors that indicate strong potential for Galderma Group AG’s stock. The US sales volumes for Nemluvio are aligning with the base case projections, supporting the $134 million forecast for the third quarter. This performance suggests that Nemluvio’s success could provide a cushion against broader market uncertainties, potentially adding to the company’s total revenues.
Furthermore, insights from the EADV congress highlight Nemluvio’s relevance in addressing key medical concerns, such as itch, which is a significant topic among physicians. The prescription trends, particularly the percentage of prescriptions accounting for two pens, are crucial indicators of market recovery post-holiday impacts. These factors collectively support the positive outlook and justify the Buy rating for Galderma Group AG.
In another report released on September 16, Goldman Sachs also maintained a Buy rating on the stock with a CHF160.00 price target.